Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
Zamagni E, Oliva S, Gay F, Capra A, Rota-Scalabrini D, D'Agostino M, Belotti A, Galli M, Racca M, Zambello R, Gamberi B, Albano D, Bertamini L, Versari A, Grasso M, Sgherza N, Priola C, Fioritoni F, Patriarca F, De Cicco G, Villanova T, Pascarella A, Zucchetta P, Tacchetti P, Fanti S, Mancuso K, Barbato S, Boccadoro M, Musto P, Cavo M, Nanni C.
Zamagni E, et al. Among authors: fioritoni f.
EClinicalMedicine. 2023 Jun 9;60:102017. doi: 10.1016/j.eclinm.2023.102017. eCollection 2023 Jun.
EClinicalMedicine. 2023.
PMID: 37396807
Free PMC article.